Clinical trialObsTerminated
The PLATON Network
The Platform for Analyzing Targetable Tumor Mutations Network (Main-study)
- Outcome
- Stopped earlySponsor Decision (Business decision)
- Phase
- Obs
- Status
- Terminated
- Study type
- Observational
- Start
- 28 October 2020
- Expected end
- 30 June 2025
- Enrollment
- 565 participants
- Sites
- 31
- Primary outcomes
- Frequency of targetable mutations in gastrointestinal cancer patients; Tumor mutations and their impact on treatment decisions in gastrointestinal cancer patients
- Sponsor
- Other
- Results posted
- No
- Last update
- 5 February 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The PLATON Network study is designed to elevate personalized therapy based on genomic tumor profiles in gastrointestinal cancer patients. Hereby, PLATON's study-design focuses on the patient's tumor molecular profiling. Within the network a web application will be developed to link clinical investigators and information on study sites, cancer patients and genetic alteration data, as well as available clinical trials at PLATON's study sites.
Detailed description public domain (ClinicalTrials.gov)
The PLATON Network is established as permanent open, multicenter, prospective, cohort study of patients with gastrointestinal cancer. The study design includes a study-specific biobank and a shared platform infrastructure for associated sub-studies and analysis projects. Within PLATON results of genetic tests of different research projects like the PLATON pilot-study (NCT04484636) as well as Next-generation deep sequencing (NGS) according to local protocols will be documented - compiling genomic tumor-profiles including tumor mutational burden (TMB) and microsatellite instability (MSI). The PLATON Network infrastructure is designed to increase the likelihood of treating the patients with an individualized therapy in available clinical studies. Therefore, molecular profiling must go hand in hand with inter-linking physicians and increasing inter-centre transparency. The feasibility of this approach will be tested in the PLATON Network, keeping in mind the vision of cancer patients receiving the best available, scientifically founded, biomarker-based care, tailored to his or her individual needs.